StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) stock

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

Sangamo Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Sangamo Therapeutics's operating cash flow for the twelve months ending Mar 31, 2026 was -$90.34M. For fiscal 2025 it was -$97.21M. The highest annual figure on record is $169.88M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$97.21M–
FY2024Dec 31, 2024-$67.14M–
FY2023Dec 31, 2023-$224.84M–
FY2022Dec 31, 2022-$223.63M–
FY2021Dec 31, 2021-$233.25M-237.3%
FY2020Dec 31, 2020$169.88M–
FY2019Dec 31, 2019-$144.40M-495.1%
FY2018Dec 31, 2018$36.55M+227.0%
FY2017Dec 31, 2017$11.18M–
FY2016Dec 31, 2016-$65.88M–
FY2015Dec 31, 2015-$33.72M–
FY2014Dec 31, 2014-$5.68M–
FY2013Dec 31, 2013-$19.48M–
FY2012Dec 31, 2012-$8.08M–
FY2011Dec 31, 2011-$25.90M–
FY2010Dec 31, 2010-$23.93M–
FY2009Dec 31, 2009-$6.14M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026-$19.28M–
Q4 FY2025Dec 31, 2025-$24.40M–
Q3 FY2025Sep 30, 2025-$28.50M-342.4%
Q2 FY2025Jun 30, 2025-$18.16M–
Q1 FY2025Mar 31, 2025-$26.15M–
Q4 FY2024Dec 31, 2024-$3.35M–
Q3 FY2024Sep 30, 2024$11.76M–
Q2 FY2024Jun 30, 2024-$26.88M–
Q1 FY2024Mar 31, 2024-$48.66M–
Q4 FY2023Dec 31, 2023-$50.54M–
Q3 FY2023Sep 30, 2023-$47.29M–
Q2 FY2023Jun 30, 2023-$60.71M–
Q1 FY2023Mar 31, 2023-$66.30M–
Q4 FY2022Dec 31, 2022-$57.05M–
Q3 FY2022Sep 30, 2022-$53.62M–
Q2 FY2022Jun 30, 2022-$53.99M–
Q1 FY2022Mar 31, 2022-$58.98M–
Q4 FY2021Dec 31, 2021-$52.71M–
Q3 FY2021Sep 30, 2021-$59.42M-279.7%
Q2 FY2021Jun 30, 2021-$52.57M-132.9%
Q1 FY2021Mar 31, 2021-$68.55M–
Q4 FY2020Dec 31, 2020-$4.30M–
Q3 FY2020Sep 30, 2020$33.07M–
Q2 FY2020Jun 30, 2020$159.99M–
Q1 FY2020Mar 31, 2020-$18.89M–
Q4 FY2019Dec 31, 2019-$20.82M–
Q3 FY2019Sep 30, 2019-$38.87M–
Q2 FY2019Jun 30, 2019-$39.59M-132.3%
Q1 FY2019Mar 31, 2019-$45.12M–
Q4 FY2018Dec 31, 2018-$40.16M–
Q3 FY2018Sep 30, 2018-$27.60M–
Q2 FY2018Jun 30, 2018$122.44M+115.6%
Q1 FY2018Mar 31, 2018-$18.13M–
Q4 FY2017Dec 31, 2017-$16.84M–
Q3 FY2017Sep 30, 2017-$15.69M–
Q2 FY2017Jun 30, 2017$56.79M–
Q1 FY2017Mar 31, 2017-$13.08M–
Q4 FY2016Dec 31, 2016-$11.77M–
Q3 FY2016Sep 30, 2016-$17.58M–
Q2 FY2016Jun 30, 2016-$16.18M–

More Sangamo Therapeutics figures

See a number that looks wrong?